Institut Bergonié and Seven and Eight Biopharmaceuticals Inc. Announce the First Patient Treated in the AGADIR Study of BDB001 in Combination with Atezolizumab and Immunogenic Radiotherapy in Solid Tumors
- May 18, 2021
- Julie Ha
The AGADIR study is sponsored by Institut Bergonié, as part of their collaboration with Seven and Eight Biopharmaceuticals Inc., to advance the development of new immunotherapies to treat cancer PARIS, France & EDISON, N.J.–(BUSINESS WIRE)–Institut Bergonié, a cancer center based in Bordeaux, and Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company specializing […]
The AGADIR study is sponsored by Institut Bergonié, as part of their collaboration with Seven and Eight Biopharmaceuticals Inc., to advance the development of new immunotherapies to treat cancer PARIS, France & EDISON, N.J.–(BUSINESS WIRE)–Institut Bergonié, a cancer center based in Bordeaux, and Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company specializing […]